Pyxis Current Deferred Revenue from 2010 to 2025
| PYXS Stock | USD 1.09 0.04 3.81% |
Current Deferred Revenue | First Reported 2010-12-31 | Previous Quarter 8.8 M | Current Value 4.4 M | Quarterly Volatility 3.3 M |
Check Pyxis Oncology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pyxis Oncology's main balance sheet or income statement drivers, such as Net Interest Income of 7.4 M, Interest Income of 7.4 M or Depreciation And Amortization of 3.1 M, as well as many indicators such as Price To Sales Ratio of 4.52, Dividend Yield of 0.0 or PTB Ratio of 0.79. Pyxis financial statements analysis is a perfect complement when working with Pyxis Oncology Valuation or Volatility modules.
Pyxis | Current Deferred Revenue |
Latest Pyxis Oncology's Current Deferred Revenue Growth Pattern
Below is the plot of the Current Deferred Revenue of Pyxis Oncology over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. Pyxis Oncology's Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pyxis Oncology's overall financial position and show how it may be relating to other accounts over time.
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
Pyxis Current Deferred Revenue Regression Statistics
| Arithmetic Mean | 2,442,664 | |
| Geometric Mean | 744,898 | |
| Coefficient Of Variation | 135.17 | |
| Mean Deviation | 2,835,538 | |
| Median | 224,000 | |
| Standard Deviation | 3,301,756 | |
| Sample Variance | 10.9T | |
| Range | 8.6M | |
| R-Value | 0.80 | |
| Mean Square Error | 4.3T | |
| R-Squared | 0.63 | |
| Significance | 0.0002 | |
| Slope | 551,358 | |
| Total Sum of Squares | 163.5T |
Pyxis Current Deferred Revenue History
About Pyxis Oncology Financial Statements
Pyxis Oncology shareholders use historical fundamental indicators, such as Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Although Pyxis Oncology investors may analyze each financial statement separately, they are all interrelated. The changes in Pyxis Oncology's assets and liabilities, for example, are also reflected in the revenues and expenses on on Pyxis Oncology's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 8.8 M | 4.4 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Pyxis Stock Analysis
When running Pyxis Oncology's price analysis, check to measure Pyxis Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pyxis Oncology is operating at the current time. Most of Pyxis Oncology's value examination focuses on studying past and present price action to predict the probability of Pyxis Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pyxis Oncology's price. Additionally, you may evaluate how the addition of Pyxis Oncology to your portfolios can decrease your overall portfolio volatility.